Drug Approval | December 10, 2021
China approves Brii Bio’s antibody combination to neutralise Covid-19
Brii Bio announces amubarvimab/romlusevimab combination received approval from NMPA
Brii Bio announces amubarvimab/romlusevimab combination received approval from NMPA
The facility will supply clinical trial materials for the development of vaccines and biologics up to Phase II stage and is expected to be fully operational by early 2023.
TIB Molbiol excels in ultra-rapid assay development for emerging infectious diseases, strongly demonstrated during the Covid-19 pandemic
The country’s top heart transplant surgeon Dr. K.R Balakrishnan to be leading the programme for Jaslok
Vaccine effectiveness of complete vaccination against the moderate-to-severe disease was at 81 per cent
The multi-target agreement covers five programmes focused on off-the-shelf vaccines for cancer and infectious disease
This agreement marks a milestone for Baidu to use its strengths in computational biology to optimize mRNA vaccine and therapy designs
The partnership will help advance GreenLight's messenger RNA Covid-19 vaccine candidate
An effectiveness result of 50 per cent achieved during the peak delta variant Covid-19 wave in India, in a highrisk study population of physicians and healthcare workers, in a hospital environment, provides insights into the efficacy and effectiveness of Covaxin
The approval is for Cytomegalovirus, a type of Herpes virus
Subscribe To Our Newsletter & Stay Updated
